MAPT and Alzheimer disease: An in vivo study demonstrated that chronic therapy of CP2 improved mitochondrial and synaptic function, reduced inflammation, decreased Aβ and phosphorylated Tau accumulation, and reduced neurodegeneration in a symptomatic APP/PS1 mouse model of AD [113].